The isolation, structures and biological activity of the neoclerodane and other natural products obtained from the Mexican hallucinogenic sage, Salvia divinorum are reviewed.
GrieveM. (1931) LeyelC.F. (ed.) A modern herbal, pp. 700–707. Penguin Books, 1976, Harmondsworth.
2.
UsherG. (1974) A dictionary of plants used by man, p. 520–521, Constable, London.
3.
UlubelenA. (2003) Cardioactive and anti-bacterial terpenoids from some Salvia species. Phytochemistry, 64, 395–399.
4.
RothB.L., BanerK., WestkaemperR., SiebertD., RiceK.C., SteinbergS., ErnsbergerP., and RothmanP.B. (2002) Salvinorin A, A potent naturally occurring non-nitrogenous K-opioid receptor agonist. Proc. Natl. Acad. Sci., USA, 99, 11934–11939.
5.
EmbodenW. (1979) Narcotic plants, pp. 93–95, Cassell, London.
6.
OrtegaA., BlountJ.F., and ManchandP.S. (1982) Salvinorin, A new trans neoclerodane diterpene from Salvia divinorum. J. Chem. Soc., Perkin Trans. 1, 2505–2508.
7.
KoreedaM., BrownL., and ValdesL.J. (1990) The absolute stereochemistry of the salvinorins. Chem. Lett., 2015–2018.
8.
ValdesL.J., BitlerW.M., HatfieldG.M., PaulA.G., and KoreedaM. (1984) Divinorin A, a psychotropic terpenoid and divinorin B from the hallucinogenic Mexican mint, Salvia divinorum.J. Org. Chem., 49, 4716–4720.
BartonD.H.R., and EladD. (1956) Columbo root bitter principles part II, The constitution of columbin. J. Chem. Soc., 2090–2095.
11.
SimG.A., HamorT.A., PaulI.C., and RobertsonJ.M. (1961) The structure of clerodin. Proc. Chem. Soc., 75–76.
12.
BartonD.H.R., CheungH.T., CrossA.D., JackmanL.M., and Martin-SmithM. (1961), Diterpenoid bitter principles, part III, The constitution of clerodin. J. Chem. Soc., 5061–5073.
13.
RogersD., UnalG.G., WilliamsD.J., LeyS.J., JoshiB.S., and RavindranathK.R. (1979), The crystal structure of 3-epicaryopterin and the reversal of the currently accepted absolute configuration of clerodin. J. C. S. Chem. Commun., 97–99.
14.
Martinez-RipoliM., FayosJ., RodriguezB., Garcia-AlvarezM.C., SavonaG., PiozziF., PaternostroM.P., and HansonJ.R. (1981) The absolute stereochemistry of some clerodane diterpenoids from Teucrium species. J. Chem. Soc., Perkin Trans. 1, 1186–1190.
15.
BrieskornC., and StehleT. (1973) Labiate bitter principles, A new compound of the clerodane type. Chem. Ber., 106, 922–924.
16.
SavonaG., PaternostroM.P., PiozziF., HansonJ.R., HitchcockP.B., and ThomasS.A. (1978) Salviarin, A new diterpenoid from Salvia splendens. J. Chem. Soc., Perkin Trans. 1, 643–646.
17.
SavonaG., PaternostroM.P., PiozziF., and HansonJ.R. (1979) Splendidin, a new trans clerodane from Salvia splendens. J. Chem. Soc., Perkin Trans. 1, 533–534.
18.
ShirotaO., NagamatsuK., and SekitaS. (2006) Neoclerodane diterpenes from the hallucinogenic sage, Salvia divinorum.J. Nat. Prod., 69, 1782–1786.
19.
ValdesL.J., ChangH.M., VisgerD.C., and KoreedaM. (2001) Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint. Salvia divinorum. Org. Lett., 3, 3935–3937.
20.
MunroT.A., and RizzacasaM.A. (2003) Salvinorins D–F, New neoclerodane diterpenoids from Salvia divinorum and an improved method for the isolation of salvinorin A. J. Nat. Prod., 66, 703–705.
21.
BighamA.K., MunroT.A., RizzacasaM.A., and Robins-BrowneR.M. (2003) Divinatorins A–C., new neoclerodane diterpenoids from the controlled sage, Salvia divinorum.J. Nat. Prod., 66, 1242–1244.
22.
LeeD.Y.W., MaZ., Liu-ChenL.Y., WangY., ChenY., CarlezonW.A., and CohenB. (2005), New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human K-opioid receptors. Bio-org. Med. Chem., 13, 5635–5639.
23.
HardingW.W., TidgewellK., SchmidtM., ShahK., DerschC.M., SnyderJ., ParrishD., DeschampsJ.R., RothmanR.B., and PrisinzanoT.E. (2005) Salvinicins A and B, New neoclerodane diterpenes from Salvia divinorum.Org. Lett., 7, 3017–3020.
24.
GreyerR.J., EckertM.R., VeitchN.C., KiteG.C., MarinP.D., KokubunT., SimmondsM.S.J., and PatonA.J. (2003) The chemotaxonomic significance of two bioactive caffeic acid esters, nepetoidins A and B in the Lamiaceae. Phytochemistry, 64, 519–528.
25.
ValdesL.J. (1986) Loliolide from Salvia divinorum.J. Nat. Prod., 49, 171.
26.
SchmidtM.S., PrisinzanoT.E., TidgewellK., HardingW., ButelmanE.R., KreekM.J., and MurryD.J. (2005), Determination of salvinorin A in body fluids by HPLC-atmospheric pressure C.I. J. Chromatog. B, 818, 221–225.
27.
PrisinzanoT.E., and RothmanR.B. (2008) Salvinorin A analogs as probes in opioid pharmacology. Chem. Rev., 108, 1732–1743.
28.
MunroT.A., RizzacasaM.A., RothB.L., TothB.A., and YanF. (2005), Studies towards the pharmacophore of Salvinorin A, A potent K-opioid receptor agonist. J. Med. Chem., 48, 345–348.
29.
HardingW.W., TidgewellK., ByrdN., CobbH., DerschC.M., ButelmanE.R., RothmanR.B., and PrisinzanoT.E. (2005) Neoclerodane diterpenes as a novel scaffold for μ-opioid receptor ligands. J. Med. Chem., 48, 4765–4771.
30.
HardingW.W., SchmidtM., TidgewellK., KannanP., HoldenK.G., GilmourB., NavarroH., RothmanR.B., and PrisinzanoT.E. (2006) Synthetic studies of neoclerodane diterpenes from Salvia divinorum, semi-synthesis of salvinicins A and B and other chemical transformations of salvinorin A. J. Nat. Prod., 69, 107–112.
31.
SimpsonD.S., KatavicP.L., LozamaA., HardingW.W., ParrishD., DeschampsJ.R., DerschC.M., PartillaJ.S., RothmanR.B., NavarroH., and PrisinzanoT.E. (2007) Synthetic studies of neoclerodane diterpenes from Salvia divinorum, preparation and opioid receptor activity of salvinicin analogues. J. Med. Chem., 50, 3596–3603.
32.
MunroT.A., Goetchius, RothB.L., VorthermsT.A., and RizzacasaM.A. (2005) Autoxidation of salvinorin A under basic conditions. J. Org. Chem., 70, 10057–10061.
33.
MaZ., and LeeD.Y.W. (2007) Revised structure of deacetyl-1, 10-didehy-drosalvinorin G. Tetrahedron Lett., 48, 5461–5464.
34.
MunroT.A., DuncanK.K., XuW., WangY., Liu-ChenL.Y., CarlezonW.A., CohenB.M., and BeguinC. (2008) Standard protecting groups create potent and selective κ-opioids, salvinorin B alkoxymethyl ethers. Bio-org. Med. Chem., 16, 1279–1286.
35.
BeguinC., DuncanK.K., MunroT.A., HoD.M., XuW., Liu-ChenL.Y., CarlesonW.A., and CohenB. (2009) Modification of the furan ring of salvinorin A; identification of a selective partial agonist at the K-opioid receptor. Bio-org. Med. Chem., 17, 1370–1380.
36.
LiY., HusbandsS.M., MahonM.F., TraynorJ.R., and RowanM.G. (2007) Isolation and chemical modification of clerodane diterpenoids from Salvia species as potential agonists at the K-opioid receptor. Chem. Biodivers., 4, 1586–1593.
37.
FontaneG., SavonaG., RodriguezB., DerschC.M., RothmanR.B., and PrisinzanoT.E. (2008) Synthetic studies of neoclerodane diterpenoids from Salvia splendens and evaluation of opioid receptor affinity. Tetrahedron, 64, 10041–10048.
38.
FontaneG., SavonaG., RodriguezB., DerschC.M., RothmanR.B., and PrisinzanoT.E. (2009) Synthetic studies of neoclerodane diterpenoids from Salvia splendens: oxidative modifications of ring A. Tetrahedron, 65, 1708–1715.
39.
TidgewellK., HardingW.W., SchmidtM., HoldenK.G., MurryD.J., and PrisinzanoT.E. (2004) A facile method for the preparation of deuterium labelled salvinorin A. Bio-org. Med. Chem. Lett., 14, 5099–5102.
40.
YanF., MosierP.D., WestkaemperR.B., StewartJ., ZjawionyJ.K., VorthermsT.A., SchefflerD.J., and RothB.L. (2005) Identification of the molecular mechanisms by which salvinorin A binds to K-opioid receptors. Biochemistry, 44, 8643–8651.
41.
KaneB.E., McCurdyC.R., and FergusonD.M. (2008) Toward a structure-based model of salvinorin A recognition of the K-opioid receptor. J. Med. Chem., 51, 1824–1830.
42.
ScheererJ.R., LawrenceJ.F., WangG.C., and EvansD.A. (2007) Asymmetric synthesis of salvinorin A, a potent K-opioid receptor agonist. J. Am. Chem. Soc., 129, 8969.
43.
NozawaM., SukaY., HoshiT., SuzukiT., and HagiwaraH. (2008) Total synthesis of the hallucinogenic neoclerodane diterpernoid salvinorin A. Org. Lett., 10, 1365–1368.
44.
KutrzebaL., DayanF., HowellJ.L., FengJ., GinerJ.L., and ZjawionyJ.K. (2007) Biosynthesis of salvinorin A proceeds through the deoxyxylulose phosphate pathway. Phytochemistry, 68, 1872–1881.
